An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new
promising noninvasive tool to detect biomarker in several cancers including lung cancer …

Background The field of liquid biopsies in oncology is rapidly expanding, with the
application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of …

Epidermal growth factor receptor (EGFR) mutations are the most common carcinogenic
driver mutations in non-small-cell lung cancer (NSCLC) patients, while invasive tissue …

Somatic mutations in the gene encoding epidermal growth factor receptor (EGFR) play an
important role in determining targeted treatment modalities in non-small cell lung cancer …

Objective: Utilizing cytology specimens for molecular testing has attracted increasing
attention in the era of personalized medicine. Cytology specimens are clinically easier to …

Circulating tumor DNA (ctDNA) isolated from plasma has great potential in identification of
gene mutation in non-small cell lung cancers (NSCLC), which is a non-invasive technique …

The advent of targeted therapy in non-small-cell lung cancer (NSCLC) has made the routine
molecular diagnosis of EGFR mutations crucial for optimal patient management. Obtaining …

Several ultra-sensitive methods for T790M in plasma cell-free DNA (cfDNA) have been
developed for lung cancer. The correlation between mutation-allele frequency (MAF) cut-off …